Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

About this update from Sonoma Pharmaceuticals, Inc.

[{"type":"text","content":"BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the appointment of Vanessa Jacoby, Chief Business and Financial Officer of Quanta Therapeutics, Inc., to its Board of Directors and to serve as Chair of its Audit Committee. Sonoma also announced the retirement of its longtime director, Dr. Jay Birnbaum. Finally, Sonoma announced the appointment of Arturo Angel as its Senior Vice President of Regulatory, Quality and Product Development.","length":760,"tagName":"p"},{"type":"text","content":"Vanessa Jacoby brings financial expertise along with extensive experience in the biotechnology and life science sectors to Sonoma's Board. She has served as a senior financial executive of several private and public companies and as an active participant on audit committees, responsible for reporting financial results and internal controls matters. Prior to joining Quanta, a clinical stage biotechnology company, Ms. Jacoby served as CFO of Shoreline Biosciences, where she played a key role in establishing two partnerships with Kite Pharma and BeiGene. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. (NASDAQ: RNA), where she led all corporate finance and planning activities and played a key role in the company's initial public offering. Ms. Jacoby is a licensed CPA in the State of California and began her career as an auditor for Ernst & Young.","length":921,"tagName":"p"},{"type":"text","content":"Arturo Angel joins Sonoma from Bausch Health Companies Inc., where he served as Executive Director of Research & Development, leading product development of pharmaceutical, over-the-counter and cosmetic products for dermal, oral and nasal administration for over 15 years. Mr. Angel brings expertise in formulation development, product characterization, manufacturing process transfers, validations and scale-ups, product registrations and approvals. Prior to his tenure at Bausch Health, Mr. Angel began his career at Dow Pharmaceutical Sciences Inc. serving as a chemist ...

More updates from Sonoma Pharmaceuticals, Inc.